Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed ...

Nutritional counseling remains a central component of obesity treatment, even in the era of highly effective weight-loss ...

Physicians describe common prior authorization challenges when treating patients for obesity and share strategies to overcome ...

The FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If ...

Both medications were prescribed as weekly injections for patients clinically classified as obese, and were recommended ...

The trends worry health experts, who say the medicines have potential to narrow differences in obesity rates among ...

Individuals who lived with obesity as children are less likely to be in work or studying in their mid-20s than their peers, ...

Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 agonist drugs form part of their treatment, new research being presented at ...

Individuals who lived with obesity as children are less likely to be in work or studying in their mid-20s than their peers, ...

GLP-1s may help reduce alcohol intake among adults with overweight or obesity, according to data presented at the European ...

President Trump said he would sign an executive order to base U.S. drug prices on what other countries pay — usually far less ...